318 results
Page 11 of 16
6-K
drh5lyop
23 Dec 10
Fda Issues Complete Response Letter for Lower-volume Glatiramer Acetate Snda
12:00am
6-K
ikh2ucoizl
14 Dec 10
Teva Files Citizen Petition Surrounding Purported Generic Version of Copaxone?
12:00am
6-K
6vhif87
9 Dec 10
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
12:00am
6-K
idv2u91emz
18 Oct 10
New Data Evaluating Laquinimod for the Treatment of Multiple Sclerosis Demonstrate Neuroprotective Effects
12:00am
6-K
3fy5tgz1
6 Oct 10
Teva to Present New Data on Copaxone? and Laquinimod at the 26TH Annual Ectrims Congress
12:00am
6-K
0nwadom7g vz59oolny
21 Sep 10
Oral Laquinimod Demonstrated Sustained Efficacy and Safety In Patients with Multiple Sclerosis
12:00am
6-K
ucn91vg rrd3
26 Jul 10
Teva Comments on Generic Lovenox? Approval
12:00am
6-K
EX-1.1
c3cfr0
18 Jun 10
Current report (foreign)
12:00am
6-K
EX-1.2
okh6hu 8husephtuc
18 Jun 10
Current report (foreign)
12:00am
424B5
yy2lv5ii 9vf
16 Jun 10
Prospectus supplement for primary offering
12:00am
6-K
n3ru4
17 May 10
Teva Provides Update on Talampanel for the Treatmentof Amyotrophic Lateral Sclerosis (Als)
12:00am
6-K
gaz90x sn41o80e
13 Apr 10
Teva Announces Copaxone? Reaches One Million Patient Years of Experience In the Treatment of Multiple Sclerosis
12:00am
6-K
5354rocskklk7vc43
25 Feb 10
Copaxone? 15-YEAR Study In Multiple Sclerosis Patients Demonstrates Robust Long-term Efficacy and Safety
12:00am
6-K
ov903ebq av2t3f6
8 Feb 10
Teva Acquires Marketing Rights for Oral Laquinimod In the Nordic and Baltic Regions
12:00am
6-K
c76 t0tzyfjt
8 Jan 10
Fda Approves Newly Revised Prescribing Information for Azilect Reducing Medication and Food Restrictions
12:00am
6-K
bd21mrdn
7 Jan 10
Fda Approves Newly Revised Prescribing Information for Azilect Reducing Medication and Food Restrictions
12:00am
6-K
l9oxld12jix
14 Dec 09
Fda Approves Newly Revised Prescribing Information for Azilect Reducing Medication and Food Restrictions
12:00am
6-K
xvb94s k2mps
1 Dec 09
Teva Announces the Submission of a Biologics License Application (Bla) for XM02 for the Treatment of Chemotherapy-induced Neutropenia
12:00am
6-K
1r10zb0ilgn4sneg98vg
10 Nov 09
Teva Files Amended Complaint Against Momenta/sandoz to Include Infringement of Three Copaxone?-related Patents
12:00am